COMP <GO>
IRMD vs MRK // EV/EBITDA & P/E VALUATION
iRadimed Corporation (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: IRMD 4
— MRK 8
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $76.68 (-10.57%) • MKT CAP: $1.10B
valuation
31.9x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.70% | 74.80% | +1.90 | IRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | 20.70% | +17.00 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 31.9x | 15.3x | +16.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | 3.42% | -1.85 | MRK | /fcf-yield <GO> |
| Operating Margin | 31.20% | 34.30% | -3.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 26.80% | 28.10% | -1.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 14.40% | 1.30% | +13.10 | IRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 2.26% | -0.89 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 51.7 | -1.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | 18.4x | +22.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $361.02B | -$359.92B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | MRK REV | IRMD GROSS % | MRK GROSS % | IRMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $65.01B | 76.7% | 74.8% | $17.2M | $12.36B |
| FY 2024 | $73.2M | $64.17B | 76.9% | 76.3% | $17.6M | $18.10B |
| FY 2023 | $65.6M | $60.12B | — | — | $13.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
MRK // BETA 0.92